BioTuesdays Feature Articles | Life Sciences News

Feature

BiondVax to start pivotal universal flu vaccine trial next year

By Len Zehr BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) expects to be Phase 3 ready in 2018 to begin pivotal testing in Europe of a universal flu vaccine with the potential to provide multi-season and multi-strain...

September 12, 2017

Feature

Profound makes leap to platform company from prostate product

By Len Zehr Arun Menawat, CEO With its recent acquisition of Royal Philips’ (NYSE:PHG; AEX:PHIA) Sonalleve business, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is making the leap from a medical device company focused on...

September 5, 2017

Feature

Zymeworks platforms validated by pharma partnerships

By Len Zehr Ali Tehrani, President and CEO Zymeworks’ (NYSE, TSX:ZYME) marquee partnerships with Merck, Eli Lilly, Celgene, GlaxoSmithKline and Daiichi-Sankyo provide validation for its next-generation oncology...

August 29, 2017

Feature

In conversation with Lloyd Segal of Repare

By Len Zehr As president and CEO of upstart Repare Therapeutics, Lloyd Segal was instrumental is arranging the initial funding to create Repare while he served as an entrepreneur-in-residence at Versant Ventures, a...

August 22, 2017

Feature

Contextual Genomics detecting genetic mutations in cancer

By Len Zehr Closely-held Contextual Genomics is giving oncologists a leg up to enhance cancer care with its new Find-It molecular test to detect genetic mutations in cancer patients. “We deliver solutions through our...

August 15, 2017

Feature

CKD patients opt to stay on Dimerix drug after trial

By Len Zehr Forty-five per cent of patients in Dimerix’s (ASX:DXB) successful Phase 2a trial in chronic kidney disease (CKD), on advice from their physician, applied for and were granted access to remain on DMX-200...

August 8, 2017

Feature

Scientus enters commercialization stage of growth, readies launch of lead product

By Len Zehr Closely-held Scientus Pharma expects to launch its first cannabis soft gel capsules for the treatment of neuropathic pain at the end of the year, to be followed in early 2018 with a soft gel for epilepsy and...

August 1, 2017

Feature

PureTech targeting dysfunctions in brain, gut, immune system

By Len Zehr With eight clinical-stage studies underway, including two pivotal trials expected to readout later this year, PureTech Health (LSE:PRTC) is taking a novel approach to drug development, targeting serious...

July 18, 2017

Feature

In conversation with John Gannon of TempTraq

By Len Zehr As president and CEO of closely-held Blue Spark Technologies and co-inventor of its newest product, TempTraq, John Gannon’s career has stretched from the aerospace industry to Wall Street, culminating in...

July 11, 2017

Feature

Klox focused on oral care launch, partner for wound care

By Len Zehr With franchises in dermatology, wound care and oral health, closely-held Klox Technologies has three near-term milestones this year: launching its oral care business with Colgate Palmolive; expanding the...

June 27, 2017

Feature

Canopy Health aims to evolve medical cannabis as a natural drug product and disrupt pharma market

By Len Zehr As president and CEO of newly formed Canopy Health Innovations, a spin off of Canopy Group (TSX:WEED), a world leading diversified cannabis company, Marc Wayne is a pioneer of the medical cannabis sector. He...

June 20, 2017

Feature

Medicure to leverage sales model to new products

By Len Zehr Medicure (TSXV:MPH) intends to leverage its unique sales and marketing model, which has fueled the growth of its Aggrastat IV platelet inhibitor, as it brings new generic products into its cardiovascular...

June 13, 2017

Feature

In conversation with Thomas Ronk of Buyins.net

By Len Zehr As the founder and CEO of Buyins.net, Thomas Ronk has created a proprietary database and trading strategy based on short sale timing and sales data that was not accessible to anyone prior to January 2005. As...

May 30, 2017

Feature

Microbix in talks with investors for Kinlytic relaunch

By Len Zehr Following a meeting with the FDA last month, Microbix Biosystems (TSX:MBX) is entertaining expressions of interest from potential partners to license or acquire its anti-clotting urokinase drug, which has...

May 23, 2017

Feature

IntelGenx has multi-faceted BD approach for its oral films

By Len Zehr With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with...

May 16, 2017

Feature

3DS’ genomic imaging for precision medicine

By Len Zehr As CEO of 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) since last September, Jason Flowerday is putting the diagnostic company on people’s radar. Unlike most diagnostic companies, 3DS’ proprietary imaging...

May 2, 2017

Feature

Titan’s next ProNeura-based implant dovetails with PD awareness month

By Len Zehr After receiving FDA approval last year for its Probuphine implant as a maintenance treatment for opioid addiction, Titan Pharmaceuticals (NASDAQ:TTNP) is employing its ProNeura drug delivery technology to...

April 25, 2017

Feature

Checkpoint targeting registration studies by end of 2018

Checkpoint Therapeutics (OTCQX:CKPT) is taking an “aggressive path forward” with its clinical programs and expects to be in registration studies at the end of 2018 with its lead targeted anti-cancer agent, CK-101, and...

April 18, 2017

Feature

Lion Biotechnologies spearheading TILs in solid tumors

By Len Zehr Lion Biotechnologies (NASDAQ:LBIO) is establishing a leading position in immuno-oncology through its tumor-infiltrating lymphocyte (TIL) technology to deliver personalized oncology therapies to patients with...

April 11, 2017

Feature

Ortho RTi developing biologic scaffold for soft issue injuries

By Len Zehr Ortho Regenerative Technologies is developing a “sticky scaffold” biologic that has the potential to be best in class to repair symptomatic lesions in shoulder tendons, knee meniscus and articular cartilage...

April 4, 2017

Feature

Profound Medical’s TULSA-PRO pilot OUS launch: paving the way for global growth

By Len Zehr After nearly a decade of R&D, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is now conducting a pilot launch of its TULSA-PRO medical device to ablate tissue in localized prostate cancer within key European...

March 28, 2017

Feature

Vyome completing enrollment in acne POC trial

By Len Zehr Closely-held Vyome Biosciences expects to enroll the final patient next month in a proof-of-concept clinical trial of its lead molecule for drug-resistant acne, VB 1953. “Our product has the potential to be...

March 21, 2017

Subscribe